ClinicalTrials.gg

Edema clinical trials

Its pipeline, or its studies — you choose. Free with an account during the beta.

The registry lists 568 studies for Edema across more than 10 countries. 97 are recruiting or about to start. 255 of them are mainly about Edema (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-13.

ClinicalTrials.gov finds 2,448 studies for Edema. How that becomes 566 here

This page counts the studies the registry files under Edema, and those it files under no condition that list Edemathemselves. Each study its search finds is placed by how the registry filed it and by the conditions it lists. ClinicalTrials.gov counts as of Nov 8, 2026. How condition pages count

  1. 2,448Found by its condition searchIt reads the conditions a study lists and their synonyms, and also titles and keywords.
  2. −1,226List Edema as a condition, but the registry did not file them under itMost often written as “Diabetic Macular Edema” (468), “Macular Edema” (206), and “Pulmonary Edema” (60). The registry filed 359 of them under no condition at all, and the others under other conditions only, most often Macular Edema (334) and Diabetic Retinopathy (159).
  3. −656Match it another way310 name it in the title, 150 in a keyword, and 196 by a synonym or other text the search reads.
  4. 566The count on this page68 of them list Edema in their own words; the registry filed them under no condition.

Status

Completed
319
Status unknown
71
Recruiting
56
Terminated
39
Not yet recruiting
33
Withdrawn
24

Phase

Phase 4
60
Phase 3
46
Phase 2
45
Phase 1
14
Early Phase 1
3

Where

United States
144
Turkey
80
France
36
Canada
33
Italy
26
Brazil
22

Who develops what

Add Edema to watchlistPro · free during the betaEvery Monday by email · turn it off any time

Every program with a company-led study here in the last two years, whatever its size: 5 programs from 4 companies, 1 with this as their studies’ main aim; 3 with a live phase 3 study; 0 primary completions in the next 12 months.

Comparator & background therapies

What other companies’ phase 2+ studies give as the comparator or the background here (its leading trial sponsor and partners left out): a sign of what new drugs are measured against, not by itself the standard of care, its prescriptions or its market.

DrugLeading trial sponsor · rightsCompanies, last 5 years
afliberceptRecent, limited
Evidence
  • NCT06011798 · Unity Biotechnology, Inc. · Phase 2 · background · “Aflibercept” · registered Aug 2023
  • NCT04079231 · Novartis · Phase 3 · comparator · “Aflibercept” · registered Aug 2019
Regeneron Pharmaceuticals28% of its industry studiesUS: Regeneron Pharmaceuticals (FDA 2011) + 5 othersEU: Bayer (EMA 2012) + 12 others11 study
RanibizumabRecent, limited
Evidence
  • NCT06305416 · incepta pharmaceuticals ltd · Phase 3 · comparator · “Lucentis” · registered Mar 2024
Novartis52% of its industry studiesUS: Hoffmann-La Roche (FDA 2006) + 3 othersEU: Novartis (EMA 2007) + 9 others11 study
DexamethasoneRecent, limited
Evidence
  • NCT05697809 · Oxular Limited · Phase 2 · comparator · “Ozurdex® Ophthalmic Intravitreal Implant” · registered Jan 2023
AbbVie11% of its industry studiesUS: off-patent, 28 generics marketedEU: Norgine (EMA 2016)11 study

Programs

“Meets, by arms” reads each study’s arms: vs its arm against the therapy’s; + X vs a combination against it; added to it plus the therapy against the therapy; studied with given together only. The next primary completion is the next phase-3 study’s when there is one.

The 5 programs — sign in to see the whole list, free: filter by phase and aim, sort by late development, direct comparisons or the next primary completion.

Primary completion in the next 12 months (0)

Live phase 2 and 3 studies of these programs. Primary completion is when the main measure’s data collection ends, as the registry states it (most are estimates); results come later, if they are announced.

None in the next 12 months.

Read from ClinicalTrials.gov, industry-led studies. Main aim: this is the study’s judged main condition; named, not the main aim: the sponsor names it, the study is about something else; registry mapping only: only the registry’s mapping put it here. Leading trial sponsor is the company leading the most industry studies of a drug, a measure of trial activity, not of rights. US and EU rights, and Approved: from the regulators’ records (FDA’s Drugs@FDA via openFDA; EMA’s medicines data) — the holder of a marketed or authorized original, generics and other companies’ versions; not rights elsewhere, nor approval for this condition. Phase 4 trial recorded, where neither lists it: a phase 4 study exists somewhere. Not read yet: labels by indication, exclusivity, licenses, line of therapy, academic comparators, sales.

What is being tested here

Drugs under test in Edema studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted

Drug classes tested here Diuretics 7 open · Loop diuretics 6 open · Corticosteroids 3 open · Thiazide diuretics 2 open · Angiogenesis inhibitors 14

Coming up

35studies finish main data collection within a year1 of them phase 3

Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.

The 10 nearest, phase 3 first

Who these studies take

Of the 56 Edema studies recruiting now, 34 (61%) set no upper age limit and 16 (29%) stop at 75 or younger. 8 (14%) take children under 18. 4 (7%) are for women only and 1 (2%) for men only; 4 (7%) take healthy volunteers.

Recruiting studies that take each age, of 56
AgeWomenMen
107 (13%)6 (11%)
1852 (93%)48 (86%)
3052 (93%)48 (86%)
4050 (89%)48 (86%)
5048 (86%)46 (82%)
6547 (84%)45 (80%)
7542 (75%)40 (71%)
8537 (66%)35 (63%)

Across all 568 studies, recruiting or not: 33% stop at 75 or younger and 28% at 65; 12% take children; 7% are for women only and 2% for men only; 21% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.

How long Edema studies take

Of 28 phase 4 interventional studies under Edema, half reached primary completion within 30 months of starting, counting those still running.

Start to primary completionEvery sponsorIndustryNon-industry
Phase 219 mo13–31 · 14 studies——
Phase 430 mo12–74 · 28 studies——
Interventional, no phase11 mo6–24 · 168 studies—11 mo6–24 · 153 studies
Observational23 mo7–47 · 85 studies—21 mo7–39 · 76 studies

Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out

What changed recently

From the registry's own updates since Oct 18, 2026.

Studies

Recruiting first, then most recently updated. Showing 50 of 568. Browse all 568 → or search them.